Friday, July 19, 2024
HomeBusinessLow dosage may be behind low efficacy of CureVac vaccine -study leader...

Low dosage may be behind low efficacy of CureVac vaccine -study leader By Reuters


Related stories

Adam Lindemann’s Venus Over Manhattan Wraps Up Latest Show-Stopping Exhibits

Founded by Adam Lindemann in 2012, Venus Over Manhattan...

100+ Smooth Pick-Up Rizz Lines For You To Rizz Up A Girl

Have you ever tried approaching someone? but failed...

Utanmaz Türkler: Exploring Cultural Nuances and Societal Impacts

Introduction "Utanmaz Türkler" translates to "Shameless Turks" in English. This...

Why Trusts Are Key to Wealth Preservation

When it comes to preserving wealth across generations, few...


© Reuters. FILE PHOTO: A dose of CureVac vaccine or a placebo is seen during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves Herman/File Ph

By Caroline Copley

BERLIN (Reuters) – The low dosage might be a key reason why CureVac’s COVID-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said on Thursday.

The German biotech’s vaccine proved only 47% effective in an initial trial, far lower than those of rivals BioNTech/Pfizer and Moderna (NASDAQ:), which are also based on mRNA technology and had efficacy rates well above 90%.

Peter Kremsner from the University Hospital in Tuebingen which is running the trial told Reuters the low efficacy is “very likely due to the dose”.

Unlike BioNTech and Moderna, CureVac did not modify the mRNA used in shot and therefore a higher dosage was not possible because of the side effects to be expected, Kremsner said.

With just 12 micrograms of mRNA per dose, the company has been seeking to position itself as a low-dose alternative to BioNTech and Moderna’s established shots with 30 and 100 micrograms per shot, respectively.

It is also easy to store and cheaper than the other mRNA shots too. The European Union has agreed to pay 12 euro ($14.32) per dose for supplies of the shot, an EU internal document shows, but has paid more than 15 euros for the other mRNA shots. However, the interim trial analysis goes some way to challenging the expectation, which was previously reflected in the company’s share price, that all mRNA vaccines are similar. The news wiped as much as 52% off the company’s value on Thursday.

See also  Managing Financеs in thе Contracting Businеss: From Invoicеs to Estimatеs

CureVac said on Wednesday that new variants had proved a headwind, but data from BioNTech and Moderna have, however, so far suggested only somewhat weaker protection against new variants.

Kremsner said he thought it was probably a “long shot” as to whether CureVac’s vaccine might turn out to be more effective when targeting a particular variant.

The disappointing results are a blow since European governments had been hoping to add it to their arsenal after age limits were imposed on the use of the Johnson & Johnson (NYSE:) and AstraZeneca (NASDAQ:) vaccines due to a link to extremely rare but potentially fatal clotting disorder.

($1 = 0.8378 euros)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Source link

Bellie Brown
Bellie Brown
Hi my lovely readers, I am Bellie brown editor and writer of I write blogs on various niches such as business, technology, lifestyle., health, entertainment, etc as well as manage the daily reports of the website. I am very addicted to my work which makes me keen on reading and writing on the very latest and trending topics. One can check my more writings by visiting

Latest stories